Drug Profile
DV 1179
Alternative Names: DV1079; DV1179Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Oligonucleotides
- Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Autoimmune-disorders in USA (Parenteral, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Inflammation in USA (Parenteral, Injection)
- 21 Dec 2015 Phase-I development for Inflammation and Autoimmune disorders is ongoing in USA